Ligand Pharmaceuticals Incorporated (LGND): Price and Financial Metrics

Ligand Pharmaceuticals Incorporated (LGND)

Today's Latest Price: $85.02 USD

0.28 (0.33%)

Updated Oct 23 4:00pm

Add LGND to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

LGND Stock Summary

  • The price/operating cash flow metric for Ligand Pharmaceuticals Inc is higher than 92.14% of stocks in our set with a positive cash flow.
  • With a year-over-year growth in debt of -30.66%, Ligand Pharmaceuticals Inc's debt growth rate surpasses merely 9.36% of about US stocks.
  • Ligand Pharmaceuticals Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 43.63%, greater than the shareholder yield of 93.29% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Ligand Pharmaceuticals Inc, a group of peers worth examining would be SEDG, LSCC, QLYS, NUAN, and SMTC.
  • LGND's SEC filings can be seen here. And to visit Ligand Pharmaceuticals Inc's official web site, go to

LGND Stock Price Chart Interactive Chart >

Price chart for LGND

LGND Price/Volume Stats

Current price $85.02 52-week high $127.80
Prev. close $84.74 52-week low $57.24
Day low $84.00 Volume 700,300
Day high $88.97 Avg. volume 383,513
50-day MA $99.70 Dividend yield N/A
200-day MA $100.36 Market Cap 1.37B

Ligand Pharmaceuticals Incorporated (LGND) Company Bio

Ligand Pharmaceuticals develops therapies that address the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. The company was founded in 1987 and is based in La Jolla, California.

LGND Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$85.02$9.59 -88%

We started the process of determining a valid price forecast for Ligand Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Ligand Pharmaceuticals Inc ranked in the 12th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Ligand Pharmaceuticals Inc, consider:

  • The company's debt burden, as measured by earnings divided by interest payments, is 0.07; that's higher than only 23.35% of US stocks in the Healthcare sector that have positive free cash flow.
  • Ligand Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 165 -- greater than 98.43% of US stocks with positive free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

BLFS, PCRX, BSX, ELAN, and EW can be thought of as valuation peers to LGND, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

LGND Latest News Stream

Event/Time News Detail
Loading, please wait...

LGND Latest Social Stream

Loading social stream, please wait...

View Full LGND Social Stream

Latest LGND News From Around the Web

Below are the latest news stories about Ligand Pharmaceuticals Inc that investors may wish to consider to help them evaluate LGND as an investment opportunity.

Global Restless Leg Syndrome Market Analysis & Future Growth Analysis Report By Product Type, Industry Application And Future Technology 2026||Ligand Pharmaceuticals Incorporated, Jazz Pharmaceuticals, Inc, Hisamitsu Pharmaceutical Co., Inc, Intas Pharmac

Data bridge Market research provides a report in which the Restless Leg Syndrome market drivers and regulations are derived from a famous SWOT analysis technique. We’ve taken up their organization profiles to really understand those key gamers and types.

OpenPR | September 28, 2020

Ligand forecasts big jump in Captisol material sales in 2021

Ligand Pharmaceuticals ([[LGND]] +5.0%) expects Captisol material sales of ~$200M in 2021 compared to its 2020 full-year expectation of $90M.The company said “recent new contracting with partners and investments in manufacturing capacity have contributed to its Captisol business operating at the highest levels in the history of the technology and...

Seeking Alpha | September 23, 2020

Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that recent new contracting with partners and investments in manufacturing capacity have contributed to its Captisol business operating at the highest levels in the history of the technology and position Captisol for major growth. Significant new clinical and regulatory developments with Evomela and Kyprolis, among other drugs, are reinforcing the role the proprietary technology serves in enabling important

Business Wire | September 23, 2020

Ligand Expands OmniAb® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of two privately held companies that strengthen and complement its OmniAb® technology platform. Ligand acquired xCella Biosciences, Inc. for $7 million in cash plus potential earnouts, and acquired Taurus Biosciences LLC for $5 million in cash plus non-transferable contingent value rights (CVRs). In addition, Ligand will invest $2.5 million in a new company, Minotaur Therapeutics, which will

Business Wire | September 10, 2020

Ligand Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc.

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its wholly-owned subsidiary, Pelican Acquisition Sub, Inc. (the “Purchaser”), is commencing a tender offer to purchase all outstanding shares of common stock of Pfenex, Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractual contingent value right per share representing the right to receive a contingent payment of $2.00 in cash, if a certain

Business Wire | August 31, 2020

Read More 'LGND' Stories Here

LGND Price Returns

1-mo -12.51%
3-mo -30.48%
6-mo -15.92%
1-year -23.63%
3-year -41.30%
5-year -7.63%
YTD -18.48%
2019 -23.15%
2018 -0.90%
2017 34.76%
2016 -6.28%
2015 103.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.738 seconds.